APM
GBT

Avidity Partners Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Avidity Partners Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-862,000
Closed -$25.2M – 115
2021
Q4 		$25.2M Buy
+862,000
New +$26.7M 0.54% 53

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Avidity Partners Management's GBT Position: Q1 2022 in Review

Avidity Partners Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 862,000 shares — an estimated $25.2M sold.

Avidity Partners Management first reported a position in GBT in Q4 2021 and held it in 1 quarter. The position peaked at $25.2M in Q4 2021. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

  • Avidity Partners Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Avidity Partners Management sold 862,000 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $25.2M.
  • Avidity Partners Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
  • Avidity Partners Management's Global Blood Therapeutics, Inc. position peaked at $25.2M in Q4 2021.
  • 204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.